# A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.

Study · id `cardio:ct-nct05421078` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05421078](<https://clinicaltrials.gov/study/NCT05421078>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05421078

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

## Technical summary

Registry record NCT05421078. Randomized; quadruple masking; primary purpose treatment. Start 2022-06-27 (actual); primary completion 2023-03-24 (actual). Results posted on 2024-09-27.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 102 participants (enrolled count; ClinicalTrials.gov record NCT05421078, source copy `cardio:ctgov-nct05421078-2024-10-29`, retrieved 2026-10-31)
- Started: 2022-06-27 (actual) (ClinicalTrials.gov record NCT05421078, source copy `cardio:ctgov-nct05421078-2024-10-29`, retrieved 2026-10-31)
- Primary completion: 2023-03-24 (actual) (ClinicalTrials.gov record NCT05421078, source copy `cardio:ctgov-nct05421078-2024-10-29`, retrieved 2026-10-31)
- Completion: 2023-04-21 (actual) (ClinicalTrials.gov record NCT05421078, source copy `cardio:ctgov-nct05421078-2024-10-29`, retrieved 2026-10-31)
- Results first posted: 2024-09-27 (ClinicalTrials.gov record NCT05421078, source copy `cardio:ctgov-nct05421078-2024-10-29`, retrieved 2026-10-31)
- Countries: Japan (ClinicalTrials.gov record NCT05421078, source copy `cardio:ctgov-nct05421078-2024-10-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05421078-2024-10-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.
- Condition: Dyslipidemia
- Condition: Hypercholesterolemia
- Condition: High Cholesterol
- Intervention (Drug): Obicetrapib
- Intervention (Drug): Placebo
- Lead sponsor: NewAmsterdam Pharma
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: NewAmsterdam Pharma (`cardio:org-newamsterdam-pharma`)

## Provenance

Content hash: 2ed989c1c959a055d87fa6eedf55dedc61cefc2e39313b86e6d2252944a25608
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
